Basic Information |
|
| Product Name： | REPAGLINIDE |
| CAS： | 108157-52-4 ;135062-02-1 |
| English Synonyms： | 2-ETHOXY-4-([(S)-3-METHYL-1-(2-PIPERIDIN-1-YL-PHENYL)-BUTYLCARBAMOYL]-METHYL)-BENZOIC ACID ; BENZOIC ACID, 2-ETHOXY-4-[2-[[(1S)-3-METHYL-1-[2-(1-PIPERIDINYL)PHENYL]BUTYL]AMINO]-2-OXOETHYL]- ; 2-ETHOXY-4-[2-[[(1S)-3-METHYL-1-[2-(1-PIPERIDINYL)PHENYL]BUTYL]AMINO]-2-OXOETHYL]-BENZOIC ACID ; (S)-2-ETHOXY-4-[2-[[[(1S)-3-METHYL-1-[2-(1-PIPERIDINYL)PHENYL]BUTYL]AMINO]-2-OXOETHYL]BENZOIC ACID ; (S)-(+)-2-ETHOXY-4-[N-[1-(2-PIPERIDINOPHENYL)-3-METHYL-1-BUTYL]AMINOCARBONYLMETHYL]BENZOIC ACID ; S-(+)-2-ETHOXY-4-[2-(3-METHYL-1-[2-(PIPERIDIN-1-YL)PHENYL]BUTYLAMINO)-2-OXOETHYL]BENZOIC ACID ; RAPAGLINIDE ; NOVONORM ; 2-ETHOXY-4-[2-[(1S)-3-METHYL-1-[2-(1-PIPERIDINYL)BUTYL]AMINO]-2-OXOETHYL]-BENZOIC ACID ; PRANDIN ; GLUCONORM ; (S)-2-ETHOXY-4-(2-(3-METHYL-1-(2-(PIPERIDIN-1-YL)PHENYL)BUTYLAMINO)-2-OXOETHYL)BENZOIC ACID ; AG-EE-623 ; AG-EE 623ZW ; REPAGLINIDE |
| MDL Number.： | MFCD00906179 |
| H bond acceptor： | 6 |
| H bond donor： | 2 |
| Smile： | CCOc1cc(ccc1C(=O)O)CC(=O)N[C@@H](CC(C)C)c2ccccc2N3CCCCC3 |
| InChi： | InChI=1S/C27H36N2O4/c1-4-33-25-17-20(12-13-22(25)27(31)32)18-26(30)28-23(16-19(2)3)21-10-6-7-11-24(21)29-14-8-5-9-15-29/h6-7,10-13,17,19,23H,4-5,8-9,14-16,18H2,1-3H3,(H,28,30)(H,31,32)/t23-/m0/s1 |
| InChiKey： | InChIKey=FAEKWTJYAYMJKF-QHCPKHFHSA-N |
Property |
|
| Comments： | OTHER NOTES: SALES RESTRICTIONS MAY APPLY BIOCHEM/PHYSIOL ACTIONS: REPAGLINIDE IS A POTENT SHORT-ACTING INSULIN SECRETAGOGUE THAT ACTS BY CLOSING ATP-SENSITIVE POTASSIUM (KATP) CHANNELS IN THE PLASMA MEMBRANE OF THE PANCREATIC BETA CELL. IT REPRESENTS A NEW CLASS OF INSULIN SECRETAGOGUES, STRUCTURALLY UNRELATED TO SULPHONYLUREAS, WHICH WERE DEVELOPED FOR THE TREATMENT OF TYPE 2 DIABETES GENERAL DESCRIPTION: THIS PRODUCT IS PROVIDED AS DELIVERED AND SPECIFIED BY THE ISSUING PHARMACOPOEIA. ALL INFORMATION PROVIDED IN SUPPORT OF THIS PRODUCT, INCLUDING MSDS AND ANY PRODUCT INFORMATION LEAFLETS HAVE BEEN DEVELOPED AND ISSUED UNDER THE AUTHORITY OF THE ISSUING PHARMACOPOEIA. FOR FURTHER INFORMATION AND SUPPORT PLEASE GO TO THE WEBSITE OF THE ISSUING PHARMACOPOEIA |
Safety information |
|
| WGK Germany： | 2 |
* If the product has intellectual property rights, a license granted is must or contact us.
2010-2025 © Chemical Cloud Database. ALL Rights Reserved.浙ICP备11020424号-1
浙公网安备 33010802004002号
中文版